A Multicenter, Adaptive, Randomized, Controlled, Trial Platform to Evaluate Safety and Efficacy Strategies and Treatments for Hospitalized Patients with Respiratory Infections

Protocol No
INF-NIAID-STRIVE
Staff Member
Mary Beth Graham
Phase
III
Summary

This trial will evaluate S-217622, an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. to see if they improve outcomes among patients hospitalized for COVID-19.
Objective
Safety, Efficacy and Tx Strategies for Hospitalized Patients with Respiratory Infections
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Other, Infectious Diseases and Immune System
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05605093